Gennady Stolyarov II Bill Andrews Bobby Ridge Mihoko Sekido
The Third Enlightenment Salon, hosted by Gennady Stolyarov II on May 27, 2018, featured excellent conversations on the rise in public awareness of transhumanism and life extension and what can be done to further increase support for life-extending medical research. Dr. Bill Andrews, Bobby Ridge (a.k.a. Robert Ridge), and Mihoko Sekido shared insights on medical science, promotion of health, and methods of communicating the forthcoming convergence of advances in a wide array of technological fields. Importantly, we addressed how anyone can get involved in the transhumanist movement and improve public acceptance of the emerging technological future.
The following were some interesting areas of discussion:
– The new Telomere Coin, which will help fund Dr. Andrews’s research efforts – http://defytime.group/
– Bobby Ridge’s forthcoming new video channel – Science-Based Species
– Aspects of online videos that help increase their reach
– Factors that contribute to longer lifespans among Okinawans
– Motivators for leading a healthier lifestyle and its relation to the recognition of the possibility of indefinite life extension in our lifetimes
– Some potential health effects of metformin and the importance of the ongoing TAME clinical trials
– What anyone can do to promote life extension and other emerging technological fields – including joining the U.S. Transhumanist Party for free on this page.
This video also contains some excerpts from the remaining conversations at the Third Enlightenment Salon, including discussions of science-based medicine, promotion of transhumanism, autonomous vehicles, and responses to the prospect of longevity escape velocity.
Along with the recorded segment, there was much discussion about future directions of transhumanist initiatives, reasonably healthy food in a refined atmosphere, and previews of excellent video compilations that will become publicly available later this year. Mr. Stolyarov looks forward to hosting more Enlightenment Salons to bring together individuals in various fields of expertise and enable them to synthesize their insights into ways of comprehensively improving the human condition.
Longevity Industry Systematized for First Time – Press Release by Biogerontology Research Foundation
CREDIT: The Biogerontology Research Foundation, Deep Knowledge Life Sciences, Aging Analytics Agency and Longevity.International platform
Editor’s Note: Below is a press release by the Biogerontology Research Foundation on the longevity industry, which has been systematized for the first time in the report entitled The Science of Longevity. This press release was originally published here.
~ Dinorah Delfin, Director of Recruitment, U.S. Transhumanist Party, February 5, 2018
For scientists, policy makers, regulators, government officials, investors and other stakeholders, a consensus understanding of the field of human longevity remains fragmented, and has yet to be systematized by any coherent framework, and has not yet been the subject of a comprehensive report profiling the field and industry as a whole by any analytical agency to date. The consortium behind this series of reports hope that they will come to be used as a sort of Encyclopedia Britannica and specialized Wikipedia of the emerging longevity industry, with the aim of serving as the foundation upon which the first global framework of the industry will be built, given the significant industry growth projected over the coming years.
Experts on the subject of human longevity, who tend arrive at the subject from disparate fields, have failed even to agree on a likely order of magnitude for future human lifespan. Those who foresee a 100-year average in the near future are considered extreme optimists by some, while others have even mooted the possibility of indefinite life extension through comprehensive repair and maintenance. As such the longevity industry has often defied real understanding and has proved a complex and abstract topic in the minds of many, investors and governments in particular.
The first of these landmark reports, entitled ‘The Science of Longevity‘, standing at almost 800 pages in length, seeks to rectify this.
Part 1 of the report ties together the progress threads of the constituent industries into a coherent narrative, mapping the intersection of biomedical gerontology, regenerative medicine, precision medicine, artificial intelligence, offering a brief history and snapshot of each. Part 2 lists and individually profiles 650 longevity-focused entities, including research hubs, non-profit organizations, leading scientists, conferences, databases, books and journals. Infographics are used to illustrate where research institutions stand in relation to each other with regard to their disruptive potential: companies and institutions specialising in palliative technologies are placed at the periphery of circular diagrams, whereas those involved with more comprehensive, preventative interventions, such as rejuvenation biotechnologies and gene therapies, are depicted as central.
In this report great care was taken to visualize the complex and interconnected landscape of this field via state of the art infographics so as to distill the many players, scientific subsectors and technologies within the field of geroscience into common understanding. Their hope was to create a comprehensive yet readily-understandable view of the entire field and its many players, to serve a similar function that Mendeleev’s periodic table did for the field of chemistry. While these are static infographics in the reports, their creators plan to create complimentary online versions that are interactive and filterable, and to convene a series of experts to analyze these infographics and continually update them as the geroscience landscapes shifts. Similar strategies are employed in Volume II to illustrate the many companies and investors within the longevity industry.
These reports currently profile the top 100 entities in each of the categories, but in producing them, analysts found that the majority of these categories have significantly more than 100 entities associated with them. One of their main conclusions upon finishing the report is that the longevity industry is indeed of substantial size, with many industry and academic players, but that it remains relatively fragmented, lacking a sufficient degree of inter-organization collaboration and industry-academic partnerships. The group plans to expand these lists in follow-up volumes so as to give a more comprehensive overview of the individual companies, investors, books, journals, conferences and scientists that serve as the foundation of this emerging industry.
Since these reports are being spearheaded by the UK’s oldest biomedical charity focused on healthspan extension, the Biogerontology Research Foundation is publishing them online, freely available to the public. While the main focus of this series of reports is an analytical report on the emerging longevity industry, the reports still delve deeply into the science of longevity, and Volume I is dedicated exclusively to an overview of the history, present and future state of ageing research from a scientific perspective.
The consortium of organizations behind these reports anticipate them to be the first comprehensive analytical report on the emerging longevity industry to date, and hope to increase awareness and interest from investors, scientists, medical personnel, regulators, policy makers, government officials and the public-at-large in both the longevity industry as well as geroscience proper by providing a report that simultaneously distills the complex network of knowledge underlying the industry and field into easily and intuitively comprehensible infographics, while at the same time providing a comprehensive backbone of chapters and profiles on the various companies, investors, organizations, labs, institutions, books, journals and conferences for those inclined for a deeper dive into the vast foundation of the longevity industry and the field of geroscience.
It is hoped that this report will assist others in visualising the present longevity landscape and elucidate the various industry players and components. Volume 2, The Business of Longevity, which at approximately 500 pages in length aims to be as comprehensive as Volume 1, is set to be published shortly thereafter, and will focus on the companies and investors working in the field of precision preventive medicine with a focus on healthy longevity, which will be necessary in growing the industry fast enough to avert the impending crisis of global aging demographics.
These reports will be followed up throughout the coming year with Volume 3 (“Special Case Studies”), featuring 10 special case studies on specific longevity industry sectors, such as cell therapies, gene therapies, AI for biomarkers of aging, and more, Volume 4 (“Novel Longevity Financial System”), profiling how various corporations, pension funds, investment funds and governments will cooperate within the next decade to avoid the crisis of demographic aging, and Volume 5 (“Region Case Studies”), profiling the longevity industry in specific geographic regions.
These reports are, however, only the beginning, and ultimately will serve as a launching pad for an even more ambitious project: Longevity.International, an online platform that will house these reports, and also serve as a virtual ecosystem for uniting and incentivizing the many fragmented stakeholders of the longevity industry, including scientists, entrepreneurs, investors, policy makers, regulators and government officials to unite in the common goal of healthspan extension and aversion of the looping demographic aging and Silver Tsunami crisis. The platform will use knowledge crowdsourcing of top tier experts to unite scientists with entrepreneurs, entrepreneurs to investors, and investors to policy-makers and regulators, where all stakeholders can aggregate and integrate intelligence and expertise from each other using modern IT technologies for these types of knowledge platforms, and all stakeholders can be rewarded for their services.
The consortium behind these reports is interested in collaboration with interested contributors, institutional partners, and scientific reviewers to assist with the ongoing production of these reports, to enhance their outreach capabilities and ultimately to enhance the overall impact of these reports upon the scientific and business communities operating within the longevity industry, and can be reached at firstname.lastname@example.org
About the Biogerontology Research Foundation:
The Biogerontology Research Foundation is a UK non-profit research foundation and public policy center seeking to fill a gap within the research community, whereby the current scientific understanding of the ageing process is not yet being sufficiently exploited to produce effective medical interventions. The BGRF funds and conducts research which, building on the body of knowledge about how ageing happens, aims to develop biotechnological interventions to remediate the molecular and cellular deficits which accumulate with age and which underlie the ill-health of old age. Addressing ageing damage at this most fundamental level will provide an important opportunity to produce the effective, lasting treatments for the diseases and disabilities of ageing, required to improve quality of life in the elderly. The BGRF seeks to use the entire scope of modern biotechnology to attack the changes that take place in the course of ageing, and to address not just the symptoms of age-related diseases but also the mechanisms of those diseases.
New Year’s Message and Prospects for Anti-Aging Biomedical Research in 2018 – Article by Victor Bjoerk
Happy new 2018, a new year and new opportunities to do things! Setting aside the arbitrary fact of how we measure time, it is nevertheless important to reflect back on the past year!
During 2017 over 40 million people died world-wide of causes that would not have happened to them if they had been biologically less than 40 years old. I think it’s completely superfluous to add that this is unethical on all levels and will eventually go down in history books like the Black Death.
There are widespread worries about global risks in everything from politics to environment, however let’s look at the statistics as I like to point out: If you are a young person in your 20s or 30s living in the western world, and you don’t age but just carry out your normal daily life with all the normal risks, you are approximately expected to live 3000-5000 years, depending on country. Also there is a lot of improvement in living standards in the rest of the world, so most countries are heading for the same demographic problem.
So the world is a very safe place to be if you are biologically young!
During 2018 I will continue to follow the biomedical research that is ongoing, and I am co-organizing the Eurosymposium on Healthy Aging in Brussels in November of this year, to bring together researchers, investors, and other goal-oriented people active in the field of aging research.
Before that, in only 2.5 months, we have the Undoing Aging conference in Berlin, which is rapidly approaching starting on the 15th of March this year.
Now there are many other interesting conferences also, but these are at least the major ones I have in mind right now when writing, since I’m not in a position to attend everything (I wish I could).
During the upcoming years, we will see a vast market flourishing to try to repair aging damage in people and extend life; some will be purposeful deceits, other things will work great in mice but not in humans; moreover, there are therapies that will work but will have unacceptable side effects. Some discoveries will make great headlines and increase our understanding, perhaps even lead to a Nobel Prize, but be useless when it comes to any reasonably short-term applications. Media will continue to publish a lot of unspecific articles about “how you will live to 150” – simplifying science and creating hype and cult of personality. Some scientists will continue to pop up in media and spread false pessimism that nothing can be done about aging. But eventually what is going to happen is that translational medicine will continue to grow and generate an incremental improvement, what has been popularized as a “longevity escape velocity”, because here we have a complex problem which no single intervention will fix.
The question it all boils down to is, “How soon?” What can YOU do to have an impact here? How do we run clinical trials on the elderly while avoiding pitfalls that can easily hurt the field?
And here’s the thing I personally care about: there are a lot of scientists working on things that can be of use to combat pathologies and extend lifespan in the elderly, but they are themselves unaware of these applications! I’ve seen it so many times to my surprise. Is it due to archaic academic structures or a lack of transdisciplinary thinking? Nevertheless it’s an observation.
What 2018 brings remains unknown at this moment of writing, but I wish all of my friends to really make the best of it!
Victor Bjoerk has worked for the Gerontology Research Group, the Longevity Reporter, and the Fraunhofer-Institut für Zelltherapie und Immunologie. He has promoted awareness throughout Europe of emerging biomedical research and the efforts to reverse biological aging.
The Good Sides of Aging? – Article by Nicola Bagalà
Editor’s Note: Nicola Bagalà in this guest article elaborates upon aging as a topic distinguished in terms of Chronological Aging and Biological Aging. This article was originally published by the Life Extension Advocacy Foundation (LEAF).
~ Kenneth Alum, Director of Publication, U.S. Transhumanist Party, October 17, 2017
Sometimes, and especially in articles aimed at mitigating people’s fear of aging, it is said that aging doesn’t come just with downsides, such as frailty and diseases, but also with upsides — for example, wisdom and a long life experience.
It is often subtly implied that these two very different aspects are two sides of the same coin, that you can’t have one without the other, and perhaps even that the ill health of old age is a fair price to pay for the benefits that also come with it.
Nothing could be further from the truth.
Setting the record straight
There are plenty of good reasons to be afraid of aging, because the diseases and disabilities it causes are very real and far from being observed only in exceptional cases. It would be foolish not to fear cancer, for example, because it is an extremely serious and often fatal condition; in the same way, and for the same reasons, it is foolish not to fear aging; perhaps, an even stronger fear is justified, because aging can and does give rise to many diseases, including cancer itself.
There’s nothing wrong with fearing aging, because it may help us steer clear from its inherent dangers, just like the fear of any other harmful thing keeps us away from it. This is true so long as by ‘aging’ we mean biological aging, which is not at all the same as chronological aging. It is very important to draw a line between the two so that we don’t end up accepting the downsides of the former, which are neither necessary nor sufficient to enjoy the benefits of the latter.
What’s the difference?
Chronological aging is a rather fancy term to indicate a very mundane thing, namely the passing of time. For as long as time will keep passing, everything will age chronologically. This is obviously a good thing because if time did not pass, the universe would stand still and nothing at all, including ourselves, would ever happen.
However, it is easy to see how chronological and biological aging are not the same thing by means of a simple observation: Although time runs essentially uniformly everywhere on Earth, different life forms have different health- and lifespans. If time passes at the same rate for me and for a cat, and yet I’m (biologically) old at age 80 while a cat is (biologically) old already at age 15, clearly there must be something else than just the passing of time that accounts for this discrepancy.
This ‘something else’ is metabolism—the intricate set of chemical reactions the bodies of living creatures perform on a daily basis for the very purpose of staying alive. As we have discussed in other articles, what we call biological aging is really just a process of damage accumulation; this damage, which eventually leads to pathologies, is caused by metabolism itself, and therefore a faster metabolism means faster aging. Different species have different metabolic rates; as a rule of thumb, the smaller the species, the faster its metabolism and thus its aging, leading to shorter health- and lifespan. This is, in a nutshell, why a cat ages faster than I do.
As a confirmation of this fact, one may observe that species in a regimen of caloric restriction tend to live longer (sometimes much longer) than their normal lifespan, and the insurgence of age-related diseases is delayed accordingly: A lower caloric intake causes metabolism to slow down; consequently, the aging process follows suit.
Interestingly, some lucky species, the so-called negligibly senescent organisms, don’t show any signs of biological aging at all with the passing of time.
At this point, you don’t have to be clairvoyant to see that biological aging implies chronological aging, but not vice-versa. No chronological aging means no time passing, and no time passing means nothing takes place, metabolism included. However, since different creatures age differently (or not at all) despite time passing at the same rate for all of them, chronological aging doesn’t imply biological aging. Quite simply, they’re not the same thing.
Render unto Caesar the things which are Caesar’s
Having cleared the difference between chronological and biological aging, we must now correctly attribute the aforementioned pros and cons of old age to each of them.
From the very definition of biological aging above, it’s clear that it is the culprit responsible for the cons—the diseases of old age.
Speaking of the pros, all possible benefits of old age—life experience, wisdom, sense of accomplishment—certainly do not come from the damage that metabolism has wrecked throughout your body over the years. Clearly, they depend on the events of your life, and thus they’re not at all granted to happen, no matter how long you live. If you spent your life in isolation doing nothing, avoiding new experiences, and not learning anything new, your wisdom as an eighty-year-old would hardly compare to that of a well-traveled, seasoned scientist or philosopher of the same age, for example. Ultimately, the benefits traditionally attributed to old age obviously depend on the passing of time (i.e., chronological aging), and most of all on the use you made of your time. Just because you’re old, you’re not automatically wise, accomplished, or well-learned.
What’s more, the debilitation that comes with biological aging makes it harder for you to relish and expand the wisdom and experience you’ve accrued over the years. So, not only does biological aging bring no benefits; it is a hindrance as well.
In conclusion, the pros and cons of old age are due to different causes, and, as such, they aren’t interdependent. The diseases of old age are not a currency you can use to buy yourself the wisdom of the aged, and thanks to the emergence of rejuvenation biotechnologies, you might relatively soon be able to enjoy the pros of old age without having to pay any undue and unfair tolls.
About Nicola Bagalà
Nicola Bagalà has been an enthusiastic supporter and advocate of rejuvenation science since 2011. Although his preferred approach to treating age-related diseases is Aubrey de Grey’s suggested SENS platform, he is very interested in any other potential approach as well. In 2015, he launched the blog Rejuvenaction to advocate for rejuvenation and to answer common concerns that generally come with the prospect of vastly extended healthy lifespans. Originally a mathematician graduated from Helsinki University, his scientific interests range from cosmology to AI, from drawing and writing to music, and he always complains he doesn’t have enough time to dedicate to all of them—which is one of the reasons he’s into life extension. He’s also a computer programmer and web developer. All the years spent learning about the science of rejuvenation have sparked his interest in biology, in which he’s planning to get a university degree.
About LIFE EXTENSION ADVOCACY FOUNDATION (LEAF)
In 2014, the Life Extension Advocacy Foundation was established as a 501(c)(3) non-profit organization dedicated to promoting increased healthy human lifespan through fiscally sponsoring longevity research projects and raising awareness regarding the societal benefits of life extension. In 2015 they launched Lifespan.io, the first nonprofit crowdfunding platform focused on the biomedical research of aging.
They believe that this will enable the general public to influence the pace of research directly. To date they have successfully supported four research projects aimed at investigating different processes of aging and developing therapies to treat age-related diseases.
The LEAF team organizes educational events, takes part in different public and scientific conferences, and actively engages with the public on social media in order to help disseminate this crucial information. They initiate public dialogue aimed at regulatory improvement in the fields related to rejuvenation biotechnology.
Bioquark, Inc., and Lakmus LLC Announce Research Collaboration to Study Novel Biopharmaceuticals for Healthy Longevity Enhancement – Press Release by Ira Pastor
Bioquark, Inc., and Lakmus LLC, announce a multi-disciplinary research collaboration to study age-reversal / longevity-enhancing bio-pharmaceutical development with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences, and the Pavlov Institute of Physiology of the Russian Academy of Sciences.
Bioquark, Inc., (http://www.bioquark.com) a life sciences company focused on the development of novel bio-products for regeneration, disease reversion, and healthy aging, and Moscow-based Lakmus LLC, a diversified investment company with business interests in pharmacies, restaurants, and real estate, announced a multi-disciplinary research collaboration with the FSBI Zakusov Institute of Pharmacology, Russian Academy of Medical Sciences (http://www.academpharm.ru/), and the Pavlov Institute of Physiology of the Russian Academy of Sciences (http://www.infran.ru/), to jointly study the pharmacotherapeutic longevity-enhancement properties of its combinatorial regenerative biologic candidates.
“We are very excited about this continued collaboration with Lakmus,” said Ira S. Pastor, CEO, Bioquark Inc. “The disciplined development of our combinatorial biologic candidates (Bioquantines) for healthy longevity enhancement, represents another important step in our continued evolution as a company focused on a broad range of therapeutic products and services in the regenerative healthcare space.”
Throughout the 20th century, natural products formed the basis for a majority of all pharmaceuticals, biologics, and consumer healthcare products used by patients around the globe, generating trillions of dollars of wealth. However, many scientists believe we have only touched the surface with what the natural world, and its range of organisms, which from a health and wellness perspective are much further advanced than human beings, has to teach us.
The integration of a complex set of newer research disciplines, including interkingdom signaling, semiochemical communication, and evolutionary biology, as well as significant recent activity in the areas of the microbiome, are highlighting a myriad of new ways that non-human bio-products can affect the human genome for positive transitions in health and wellness dynamics.
“Bioquark has spent several years studying the natural ability of many species to turn back biological time in order to maintain health, fitness, and survival, developing a broad understanding of the combinatorial biochemical approaches they use to control nested hierarchies of disease (i.e., gene, cell, tissue, organism, environment),” said Dr. Sergei Paylian, Founder, CSO, and President, Bioquark Inc. “This research initiative is one more step in the path in allowing humans to recapture these capabilities to effectively counter our unfortunate progression into aging, disease, and degeneration.”
About Bioquark, Inc.
Bioquark Inc. is focused on the development of natural biologic based products, services, and technologies, with the goal of curing a wide range of diseases, as well as effecting complex regeneration. Bioquark is developing both biological pharmaceutical candidates, as well as products for the global consumer health and wellness market segments.
Description by LEAF: Please enjoy this interview with Dr. Aubrey de Grey, Chief Science Officer and Co-founder of SENS Research Foundation — one of the most successful advocacy and fundraising initiatives supporting breakthrough research on the main mechanisms of aging and age-related diseases.
In this video Dr. de Grey speaks about the progress in developing interventions to tackle age-related damages identified by SENS as the main ones.
Interviewer – LEAF/Lifespan.io Board member Elena Milova.
Dr. de Grey received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. He is Editor-in-Chief of Rejuvenation Research , is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations.
The Transhumanist Party is pleased to announce the revitalization of an ongoing official activism project – one that all members, irrespective of geographical location, can easily join. This is a project that utilizes our favored approach of direct, individually attainable action toward the creation of a brighter future.
You can personally help advance the fight against a multitude of diseases – such as Alzheimer’s Disease, Parkinson’s Disease, and many cancers.
The Longevity Meme Folding@home team – a group of volunteers who donate their computing power to perform protein-folding simulations that could one day result in cures for major diseases and the lengthening of human lifespans – has been operating for years, contributing otherwise idle computer resources to actual meaningful biological research.
To take part in this effort, just download the client for the Folding@home project at http://folding.stanford.edu/. Then join The Longevity Meme team here, and your computer will do the rest over time. I have personally been engaged in this effort for over six years.
If you would like a digital reward for contributing to this project, I am able to give five levels of digital Open Badges via Credly. Here is a page describing the various tiers of badges. Once you have reached the requisite number of Folding@home points to claim each badge, just contact me via e-mailhere with a message that includes your user name and an e-mail address.